Fig. 6

In-vivo therapeutic efficacy of AT101. A Timeline that recapitulates the scheduling of the treatment. AT101 was administered twice a week at a dosage of 1.5 mg/kg, the last treatment was administered at day 42, the experimental endpoint was set up at day 50. B Line graph that recapitulates the tumor growth trend of the two experimental groups. In dashed line the tumor growth trend of the group of mice treated with PBS (n = 7) is reported; in continuous line the tumor growth trend of the group of mice treated with AT101 (n = 7) is reported. Data were represented as mean ± standard error (SE). C Kaplan–Meier curve of mouse survival: the survival of mice treated with AT101 was compared with the mice treated with PBS (dashed line). In dashed line the survival curve of the group of mice treated with PBS (n = 7) is reported; in continuous line the survival curve of the group of mice treated with AT101 (n = 7) is reported. P-value < 0.0001 was calculated using log rank test